Stock Expert AI

WisdomTree BioRevolution Fund (WDNA) Holdings

For informational purposes only. Not financial advice.

Quick Answer

WisdomTree BioRevolution Fund (WDNA) has a last stored price of $23.55, as of the Oct 2, 2026 trading session. It has a 0.45% expense ratio and $2M in assets under management.

Holdings and weights below are as of Mar 15, 2026. In the stored portfolio snapshot, the largest listed holding is Moderna Inc (MRNA) at 4.46%, and the largest sector allocation is Healthcare at 91.9%.

Data Sources: Yahoo Finance · Financial Modeling Prep

WisdomTree BioRevolution Fund (WDNA) ETF — Price, Holdings & Analysis

ETF Overview

WDNA aims to capture the growth potential of companies at the forefront of the bio-revolution, focusing on those expected to be significantly impacted by advancements in genetics and biotechnology. The fund tracks the BioRevolution Index, providing exposure to companies listed globally. WDNA utilizes a representative sampling strategy, meaning it invests in a carefully selected subset of the index's constituents that collectively mirror the risk, return, and other characteristics of the entire index. This approach allows WDNA to efficiently track the index while managing costs. The fund's top holdings include companies like Moderna Inc (4.46%), Johnson & Johnson (2.97%), and Eli Lilly and Co (2.83%). WDNA is heavily concentrated in the Healthcare sector (91.9%), with smaller allocations to Basic Materials (5.0%) and Consumer Defensive (3.1%). The fund is non-diversified, indicating a concentrated investment approach within the bio-revolution theme, making it suitable for investors seeking targeted exposure to this specific area.

Risk Metrics

WDNA's concentration in the Healthcare sector (91.9%) exposes it to sector-specific risks, meaning that the fund's performance is closely tied to the performance of the healthcare industry and any adverse events affecting this sector could significantly impact the fund's value. The fund's non-diversified status further amplifies concentration risk, as a smaller number of holdings contribute a larger portion of the fund's overall performance. As of 2026-03-15, WDNA has a beta of 1.69, indicating higher volatility compared to the broader market. The expense ratio of 0.45% will create a drag on returns, especially in periods of lower performance. Their risk tolerance and investment horizon may be worth researching before investing in WDNA, given its sector concentration, non-diversified nature, and relatively high beta.
  • Beta: 1.69

Expense Ratio

0.45%

What does WDNA hold?

HoldingWeight
Moderna Inc (MRNA)4.46%
Johnson & Johnson (JNJ)2.97%
Eli Lilly and Co (LLY)2.83%
Structure Therapeutics Inc ADR (GPCR)2.69%
Stoke Therapeutics Inc (STOK)2.64%
Pfizer Inc (PFE)2.50%
Natera Inc (NTRA)2.44%
Amgen Inc (AMGN)2.43%
BioNTech SE ADR (BNTX)2.41%
AstraZeneca PLC (AZN.L)2.24%

This fund data is more than 45 days old; verify current holdings with the issuer.

How Is the Fund Allocated?

SectorWeight
Healthcare91.9%
Basic Materials5.0%
Consumer Defensive3.1%
CountryWeight
United States78.9%
Denmark4.8%
United Kingdom4.6%
Switzerland3.9%
Germany3.8%
Netherlands2.0%
Japan1.1%
Belgium0.5%
Australia0.3%
Other0.1%

Dividend Yield

0.00%

Questions & Answers

What is WDNA and what does it track?

The WisdomTree BioRevolution Fund (WDNA) is a sector equity ETF that seeks to track the investment results of the BioRevolution Index.

This index is designed to provide exposure to equity securities of exchange-listed companies globally that are expected to be significantly transformed by advancements in genetics and biotechnology.

What is the expense ratio for WDNA?

The expense ratio for WDNA is 0.45%. This means that for every $10,000 invested in the fund, $45 is deducted annually to cover operating expenses.

While 0.45% is not extremely high, it's important to consider this cost as it will impact the overall return of the investment. When evaluating WDNA, investors should compare its expense ratio to those of similar sector equity ETFs to determine if it offers competitive value.

What are the top holdings in WDNA?

As of 2026-03-15, the top holdings in WDNA include Moderna Inc (4.46%), Johnson & Johnson (2.97%), and Eli Lilly and Co (2.83%).

These companies represent a significant portion of the fund's overall portfolio and reflect its focus on the bio-revolution theme. Other notable holdings include Structure Therapeutics Inc ADR (2.69%) and Stoke Therapeutics Inc (2.64%).

Is WDNA a good long-term investment?

Whether WDNA is a suitable long-term investment depends on an individual investor's risk tolerance, investment goals, and time horizon. WDNA offers targeted exposure to the bio-revolution theme, which may present long-term growth opportunities.

However, the fund's concentration in the Healthcare sector (91.9%) and its non-diversified nature introduce sector-specific risks.

How does WDNA compare to similar ETFs?

WDNA distinguishes itself through its specific focus on companies expected to be significantly transformed by advancements in genetics and biotechnology. While other healthcare or biotechnology ETFs may offer broader exposure, WDNA provides a more targeted approach to the 'bio-revolution' theme.

Its expense ratio is 0.45%. As of 2026-03-15, WDNA has $0.00B in assets under management.

Does WDNA pay dividends?

As of 2026-03-15, the WisdomTree BioRevolution Fund (WDNA) has a dividend yield of 0.00%. This indicates that the fund does not currently distribute dividends to its shareholders.

Investors seeking income-generating investments may want to consider other ETFs with a history of dividend payments.

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Data provided for informational purposes only.

Written by machine, not reviewed page by page. Editorial oversight is systemic: the rules and the sources are checked, individual pages are not.